MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study

Phase 1
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2009-03-19
Last Posted Date
2009-03-23
Lead Sponsor
Pfizer
Target Recruit Count
50
Registration Number
NCT00864786
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip

Phase 3
Terminated
Conditions
Osteoarthritis
Interventions
Biological: tanezumab
Other: IV placebo
First Posted Date
2009-03-18
Last Posted Date
2021-02-26
Lead Sponsor
Pfizer
Target Recruit Count
607
Registration Number
NCT00864097
Locations
🇦🇹

LKH-Medizinische Universitatsklinik Graz, Graz, Austria

🇦🇹

Nuhr Zentrum, Senftenberg, Austria

🇦🇹

ClinPharm International GmbH, Wien, Austria

and more 70 locations

Tanezumab and Nerve Function In Arthritis Patients

Phase 3
Terminated
Conditions
Osteoarthritis
Interventions
Biological: tanezumab
Other: Placebo
First Posted Date
2009-03-18
Last Posted Date
2021-02-04
Lead Sponsor
Pfizer
Target Recruit Count
220
Registration Number
NCT00863772
Locations
🇺🇸

NEA Baptist Clinic, Jonesboro, Arkansas, United States

🇺🇸

JDP Medical Research, LLC, Aurora, Colorado, United States

🇺🇸

Alpine Neurology, Centennial, Colorado, United States

and more 92 locations

Tanezumab in Osteoarthritis of the Hip or Knee (2)

Phase 3
Completed
Conditions
Osteoarthritis
Interventions
Biological: tanezumab 10 mg
Biological: tanezumab 5 mg
Other: placebo
First Posted Date
2009-03-17
Last Posted Date
2021-05-17
Lead Sponsor
Pfizer
Target Recruit Count
849
Registration Number
NCT00863304
Locations
🇺🇸

Greystone Medical Research, LLC, Birmingham, Alabama, United States

🇺🇸

Saadat Ansari, MD, Huntsville, Alabama, United States

🇺🇸

Coastal Clinical Research, Inc., Mobile, Alabama, United States

and more 91 locations

Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction

Phase 2
Completed
Conditions
Erectile Dysfunction
Interventions
First Posted Date
2009-03-17
Last Posted Date
2009-04-08
Lead Sponsor
Pfizer
Target Recruit Count
39
Registration Number
NCT00862888
Locations
🇬🇧

Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Treatment A
Drug: Treatment C
Drug: Treatment B
First Posted Date
2009-03-17
Last Posted Date
2009-06-24
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00862667
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

Phase 1
Completed
Conditions
Hepatitis C Virus
Interventions
Drug: Pharmacokinetics
First Posted Date
2009-03-13
Last Posted Date
2009-07-08
Lead Sponsor
Pfizer
Target Recruit Count
14
Registration Number
NCT00861458
Locations
🇧🇪

Pfizer Investigational Site, Bruxelles, Belgium

A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: CP- 690,550 and Tacrolimus
Drug: CP- 690,550 and Cyclosporine
First Posted Date
2009-03-12
Last Posted Date
2009-08-13
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT00860496
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

Phase 4
Completed
Conditions
Falciparum Malaria
Interventions
Drug: Flavoquine®, Camoquin® Suspension
First Posted Date
2009-03-11
Last Posted Date
2010-04-21
Lead Sponsor
Pfizer
Target Recruit Count
38
Registration Number
NCT00859807
Locations
🇮🇳

Pfizer Investigational Site, Navi Mumbai, Maharashtra, India

Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA

Phase 4
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
First Posted Date
2009-03-10
Last Posted Date
2013-09-11
Lead Sponsor
Pfizer
Target Recruit Count
91
Registration Number
NCT00858780
Locations
🇸🇪

Pfizer Investigational Site, Uppsala, Sweden

© Copyright 2025. All Rights Reserved by MedPath